JP2021524439A5 - - Google Patents
Info
- Publication number
- JP2021524439A5 JP2021524439A5 JP2020564427A JP2020564427A JP2021524439A5 JP 2021524439 A5 JP2021524439 A5 JP 2021524439A5 JP 2020564427 A JP2020564427 A JP 2020564427A JP 2020564427 A JP2020564427 A JP 2020564427A JP 2021524439 A5 JP2021524439 A5 JP 2021524439A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- groups
- substituted
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024098452A JP2024125338A (ja) | 2018-05-14 | 2024-06-19 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671047P | 2018-05-14 | 2018-05-14 | |
| US62/671,047 | 2018-05-14 | ||
| PCT/US2019/032292 WO2019222269A1 (en) | 2018-05-14 | 2019-05-14 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098452A Division JP2024125338A (ja) | 2018-05-14 | 2024-06-19 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524439A JP2021524439A (ja) | 2021-09-13 |
| JP2021524439A5 true JP2021524439A5 (enExample) | 2022-05-20 |
| JP7508375B2 JP7508375B2 (ja) | 2024-07-01 |
Family
ID=67002352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564427A Active JP7508375B2 (ja) | 2018-05-14 | 2019-05-14 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
| JP2024098452A Pending JP2024125338A (ja) | 2018-05-14 | 2024-06-19 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098452A Pending JP2024125338A (ja) | 2018-05-14 | 2024-06-19 | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11827664B2 (enExample) |
| EP (1) | EP3794009A1 (enExample) |
| JP (2) | JP7508375B2 (enExample) |
| KR (1) | KR20210021457A (enExample) |
| CN (2) | CN119285591A (enExample) |
| AU (2) | AU2019271126B2 (enExample) |
| BR (1) | BR112020023277A2 (enExample) |
| CA (1) | CA3100333A1 (enExample) |
| CL (1) | CL2020002957A1 (enExample) |
| CO (1) | CO2020015380A2 (enExample) |
| EA (1) | EA202092727A1 (enExample) |
| IL (2) | IL309891B2 (enExample) |
| MX (2) | MX2020012366A (enExample) |
| PE (1) | PE20211917A1 (enExample) |
| PH (1) | PH12020551941A1 (enExample) |
| SG (1) | SG11202011311YA (enExample) |
| UA (1) | UA130486C2 (enExample) |
| WO (1) | WO2019222269A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013119985A1 (en) | 2012-02-09 | 2013-08-15 | University Of Kansas | C-terminal hsp90 inhibitors |
| KR20210021457A (ko) | 2018-05-14 | 2021-02-26 | 리아타 파마슈티컬즈, 아이엔씨. | 열충격 단백질 경로와 연관된 질환의 치료를 위한 변형된 당기를 가진 바이아릴 아마이드 |
| KR102551319B1 (ko) | 2018-05-14 | 2023-07-05 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020391106B2 (en) | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| WO2022108984A1 (en) | 2020-11-19 | 2022-05-27 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
| WO2023039293A1 (en) * | 2021-09-13 | 2023-03-16 | Rubedo Life Sciences, Inc. | Coumarin derivatives of sugar analogs and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06501465A (ja) | 1990-09-07 | 1994-02-17 | シェリング・コーポレーション | 抗ウイルス化合物 |
| DE19512886A1 (de) | 1995-04-06 | 1996-10-10 | Bayer Ag | Substituierte Cycloalkene |
| FR2792320B1 (fr) | 1999-04-19 | 2003-05-09 | Hoechst Marion Roussel Inc | Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments |
| EP1344780A4 (en) | 2000-11-30 | 2004-01-28 | Kissei Pharmaceutical | GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION |
| JP4263095B2 (ja) | 2001-09-21 | 2009-05-13 | ノバルティス アクチエンゲゼルシャフト | Ａｃｅおよびｎｅｐの両阻害剤としてのピラン誘導体 |
| US7208630B2 (en) | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| WO2010096650A1 (en) | 2009-02-20 | 2010-08-26 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| WO2006050501A2 (en) | 2004-11-03 | 2006-05-11 | University Of Kansas | Novobiocin analogues as anticancer agents |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| WO2007025943A2 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| CA2669687C (en) | 2006-11-15 | 2013-09-10 | Forest Laboratories Holdings Limited | Phthalazine derivatives |
| DE102007002715A1 (de) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| KR101313804B1 (ko) | 2007-03-20 | 2013-10-01 | 쿠리스 인코퍼레이션 | Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘 |
| US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| SG187502A1 (en) | 2008-02-01 | 2013-02-28 | Takeda Pharmaceutical | Oxim derivatives as hsp90 inhibitors |
| FR2928645A1 (fr) | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| WO2010014617A1 (en) | 2008-07-28 | 2010-02-04 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
| WO2011041593A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| US20130116227A1 (en) | 2010-07-13 | 2013-05-09 | Dainippon Sumitomo Pharma Co., Ltd. | Biaryl amide derivative or pharmaceutically acceptable salt thereof |
| CN103596955B (zh) | 2011-04-05 | 2016-11-16 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
| WO2012162054A1 (en) | 2011-05-20 | 2012-11-29 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| WO2013112548A1 (en) | 2012-01-23 | 2013-08-01 | University Of South Florida | Gamma-aapeptides with potent and broad-spectrum antimicrobial activity |
| WO2013119985A1 (en) | 2012-02-09 | 2013-08-15 | University Of Kansas | C-terminal hsp90 inhibitors |
| US9422230B2 (en) | 2013-05-09 | 2016-08-23 | Council Of Scientific And Industrial Research | Process for the preparation of an anticonvulsant agent pregabalin hydrochloride |
| EP3066072B1 (en) | 2013-11-07 | 2021-11-03 | The University of Kansas | Biphenylamide derivative hsp90 inhibitors |
| EP3068778B1 (en) | 2013-11-11 | 2025-02-19 | The University of Kansas | Coumarin based hsp90 inhibitors with urea and ether substituents |
| AU2015274265B2 (en) | 2014-06-13 | 2020-05-21 | The University Of Kansas | Triazole modified coumarin and biphenyl amide-based Hsp90 inhibitors |
| CN106536498A (zh) | 2014-06-24 | 2017-03-22 | 堪萨斯大学 | 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺 |
| KR20210021457A (ko) | 2018-05-14 | 2021-02-26 | 리아타 파마슈티컬즈, 아이엔씨. | 열충격 단백질 경로와 연관된 질환의 치료를 위한 변형된 당기를 가진 바이아릴 아마이드 |
-
2019
- 2019-05-14 KR KR1020207033977A patent/KR20210021457A/ko active Pending
- 2019-05-14 US US17/055,331 patent/US11827664B2/en active Active
- 2019-05-14 PE PE2020001859A patent/PE20211917A1/es unknown
- 2019-05-14 JP JP2020564427A patent/JP7508375B2/ja active Active
- 2019-05-14 EA EA202092727A patent/EA202092727A1/ru unknown
- 2019-05-14 CN CN202411057163.3A patent/CN119285591A/zh active Pending
- 2019-05-14 CN CN201980046311.2A patent/CN112513058B/zh active Active
- 2019-05-14 WO PCT/US2019/032292 patent/WO2019222269A1/en not_active Ceased
- 2019-05-14 MX MX2020012366A patent/MX2020012366A/es unknown
- 2019-05-14 SG SG11202011311YA patent/SG11202011311YA/en unknown
- 2019-05-14 MX MX2025007723A patent/MX2025007723A/es unknown
- 2019-05-14 IL IL309891A patent/IL309891B2/en unknown
- 2019-05-14 BR BR112020023277-7A patent/BR112020023277A2/pt unknown
- 2019-05-14 CA CA3100333A patent/CA3100333A1/en active Pending
- 2019-05-14 IL IL278698A patent/IL278698B2/en unknown
- 2019-05-14 EP EP19732770.3A patent/EP3794009A1/en active Pending
- 2019-05-14 AU AU2019271126A patent/AU2019271126B2/en active Active
- 2019-05-14 UA UAA202007914A patent/UA130486C2/uk unknown
-
2020
- 2020-11-13 PH PH12020551941A patent/PH12020551941A1/en unknown
- 2020-11-13 CL CL2020002957A patent/CL2020002957A1/es unknown
- 2020-12-09 CO CONC2020/0015380A patent/CO2020015380A2/es unknown
-
2023
- 2023-10-12 US US18/485,699 patent/US12595278B2/en active Active
-
2024
- 2024-06-19 JP JP2024098452A patent/JP2024125338A/ja active Pending
- 2024-11-29 AU AU2024267017A patent/AU2024267017A1/en active Pending